LifeStance Health Group (NASDAQ:LFST) Now Covered by Analysts at Canaccord Genuity Group

Research analysts at Canaccord Genuity Group began coverage on shares of LifeStance Health Group (NASDAQ:LFST) in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 20.66% from the stock’s previous close.

A number of other analysts have also recently commented on the stock. William Blair reaffirmed an “outperform” rating on shares of LifeStance Health Group in a research report on Friday, February 28th. The Goldman Sachs Group upgraded LifeStance Health Group from a “neutral” rating to a “buy” rating and set a $10.00 target price on the stock in a research report on Monday, December 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

LifeStance Health Group Stock Performance

NASDAQ:LFST opened at $6.63 on Thursday. LifeStance Health Group has a 52 week low of $4.64 and a 52 week high of $8.61. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. The firm’s fifty day moving average is $7.52 and its 200-day moving average is $7.34. The firm has a market cap of $2.55 billion, a P/E ratio of -25.50 and a beta of 1.27.

Insider Activity at LifeStance Health Group

In related news, insider Lisa K. Miller sold 18,845 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $6.90, for a total value of $130,030.50. Following the transaction, the insider now directly owns 339,810 shares in the company, valued at $2,344,689. This trade represents a 5.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LFST. Intech Investment Management LLC bought a new stake in shares of LifeStance Health Group during the third quarter worth about $311,000. Charles Schwab Investment Management Inc. boosted its stake in LifeStance Health Group by 36.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,104,453 shares of the company’s stock valued at $7,731,000 after purchasing an additional 297,723 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in LifeStance Health Group by 10.5% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 81,741 shares of the company’s stock valued at $572,000 after purchasing an additional 7,798 shares during the last quarter. Townsquare Capital LLC bought a new stake in LifeStance Health Group during the 3rd quarter worth approximately $73,000. Finally, MetLife Investment Management LLC raised its stake in shares of LifeStance Health Group by 14.3% in the third quarter. MetLife Investment Management LLC now owns 80,422 shares of the company’s stock worth $563,000 after purchasing an additional 10,084 shares during the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.